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Abstract
Background: Matrix metalloproteinases (MMPs) play an important role in the modeling and
remodeling of the extracellular matrix in both physiologic and pathologic states and thus plays an
important role in tumor progression. Human collagenase-3 (MMP-13) is a member of matrix
metalloproteinase family of enzymes that was originally identified in breast carcinomas and
subsequently detected during fetal ossification and in arthritic processes.
Aim: The present study was designed to investigate the expression MMP-13 and to correlate its
expression with clinicopathological parameters in chondrosarcoma of the jaws.
Methods:  Archival tumor tissues from 11 patients with chondrosarcoma of the jaws were
analyzed by immunohistochemistry for the expression of MMP-13. Clinical information was
obtained through the computerized retrospective database from the tumor registry between 1998
to 2006.
Results: Eight of 11 cases (72.8 %) of chondrosarcomas showed a positive reaction for MMP-13,
whereas two cases of normal cartilage were negative for this collagenase. As regard the
clinicopathological parameters, there was no correlation between MMP-13 expression and sex, age
and tumor site. While, there were significant associations between MMP-13 expression and both
of mitotic counts and necrosis. On the other hand, there was a significant difference between low
and high grade tumors (P < 0.05) regarding MMP-13 expression. Also, there was no significant
correlation between MMP-13 expression in primary lesions and their local recurrence.
Conclusion: MMP-13 is expressed in the majority of chondrosarcoma of the jaws. It is also
noteworthy that the expression of MMP-13 may be related to tumor biological aggressiveness and
used to aid in predicting patient's poor prognosis.
Background
Chondrosarcoma, a malignant cartilage-forming mesen-
chymal tumor, displays a wide range of clinical behavior
that can be difficult to predict with histological analysis
[1,2]. These tumors account for approximately 25% of all
malignant tumors arising from the skeletal system [3], but
are considered by most authorities to involve the jaws
only rarely; probably less than 1% of all chondrosarcomas
arise in the head and neck area [4].
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Controversies surrounding the relationship between
chondrosarcoma of the jaws and chondrosarcoma of the
skeleton have revolved around their biologic behavior,
histopathological features and clinical response to con-
servative therapy. Chondrosarcoma of jaws is locally
aggressive with a high recurrence rate but rarely metasta-
size to distant sites [5]. If chondrosarcoma spreads from
its primary site (i.e., metastasizes), it usually spreads to
the lungs. Metastasis is rare with low-grade tumors, but
has been seen, even up to 10 years after diagnosis [6].
About half of grade III and nearly all dedifferentiated
chondrosarcomas will metastasize. Up to 13% of recur-
rent chondrosarcomas are of a higher grade than the orig-
inal neoplasm [7,8].
Conventional chondrosarcomas can be categorized
according to their location in bone into central, periph-
eral, and juxtacortical chondrosarcomas. Rare subtypes of
chondrosarcoma, including dedifferentiated, mesenchy-
mal, and clear cell chondrosarcoma are discerned,
together constituting 10%–15% of all chondrosarcomas
[9]. Clear cell chondrosarcoma is a low -grade malignant
tumor and tends to metastasis rarely [10]. While, aggres-
sive chondrosarcoma subtypes, such as dedifferentiated
and mesenchymal chondrosarcomas bear a poor progno-
sis [11].
Histological grading is the best and most commonly used
marker at present for the prognosis of chondrosarcomas;
however, it is also subject to interobserver variability [12].
This is worrisome, because therapy for grade I and grade II
chondrosarcoma may differ. Wide surgical excision
remains the best available treatment for intermediate-to
high-grade tumors [9]. Most treatment failures are due to
local recurrences [5].
Currently, treatment decisions in chondrosarcomas are
guided by clinical-pathological factors such as age, sex,
metastasis, recurrence, and histological grade. Although
useful, these factors fail to provide definitive information
regarding the overall aggressiveness of a tumor and its
potential to recur. In theory, a factor that consistently
identified patients at risk for recurrent disease would help
to improve disease-free survival by allowing physicians to
select high-risk patients for more aggressive treatment. In
addition, identification of a biological marker of aggres-
sive disease would help to provide new avenues for
rational drug design targeted against specific molecular
defects [13].
In recent years, several biologic markers have been identi-
fied that they may provide additional diagnostic and
prognostic information in the management of chondrosa-
rcomas [14].
The matrix metalloproteinases (MMPs) comprise a family
of at least 25 enzymes that degrade the extracellular matrix
[15]. These enzymes operate during normal development
in tissue differentiation and remodeling [16,17], but are
also active under pathological conditions to cause inflam-
matory disease, degradation of bone [18] and cartilage
[19], as well as tumor metastasis [20,21]. They are secreted
as inactive latent forms, depend upon a zinc-binding
active site, and are inhibited by specific proteins referred
to as the tissue inhibitors of matrix metalloproteinases or
TIMPs [22-24]. In general, these MMPs enzymes are clas-
sified according to their substrate specificity and structural
similarities [25-27]. There are four major subgroups: (a)
the collagenases degrade collagen types I, II and III [25],
(b) the gelatinases act on types IV, V, VII and X collagens
[28], (c) elastin and the stromelysins shows a broader spe-
cificity, acting on proteoglycans, laminin, and fibronec-
tion [26] and (d) MT-MMPs that represent membrane-
bound forms of the enzymes, which activate latent MMP-
2 and can cleave collagen at the classic site [29]. MMPs
expression is differentially regulated by several growth fac-
tors [18].
Human collagenase-3 (MMP-13) is a recently identified
member of the matrix metalloproteinase (MMP) family
that was originally isolated from breast carcinoma [30].
Biochemical characterization of colloagenase-3 has
revealed that it is a very potent enzyme that, after activa-
tion through a proteolytic cascade mechanism, displays a
broad spectrum of activity against connective tissue com-
ponents [31]. In addition to its proteolytic activity on
fibrillar collagens, collagenase-3 is also a powerful gelati-
nase and may thus contribute to further degradation the
initial cleavage products of collagenolysis to small frag-
ments suitable for further metabolism [32]. Very recent
studies have provided that collagenase-3 may also
degrade the large cartilage proteoglycan aggrecan [33] and
other components of the extracellular matrix and base-
ment membranes, including type IV collagen, fibronectin,
and tenascin [34].
Preliminary studies on the prognostic value of colla-
genase-3 in breast cancer have revealed that this enzyme is
a marker of poor clinical outcome in breast cancer
patients [35]. In addition, recent studies have shown that
collagenase-3 is also over-expressed by a subset of squa-
mous cell carcinomas with extensive local invasion [36-
38], but has only rarely been described in connective tis-
sue tumors [39,40]. To date, there have been no reported
among the English language literature describing the pos-
sible production of this enzyme by chondrosarcoma of
the jaws. In this regard, the finding that collagenase-3 is
produced by chondrocytes during human fetal develop-
ment [41,42] and in joint-destructive processes [43,44]
prompted us to examine the possibility that this enzymeDiagnostic Pathology 2008, 3:26 http://www.diagnosticpathology.org/content/3/1/26
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could be also associated with tumor processes involving
these cells. The present study was designed to evaluate
MMP-13 immunohistochemistry for its presence in a
series of chondrosarcoma of the jaws as well as normal
cartilage. It is also aimed to investigate relation between
its expression and clinico-pathological parameters of this
tumor.
Methods
Patients with chondrosarcoma of the jaws were treated by
surgical resection as a primary means of disease control.
Of the treated patients, eleven had archival paraffin-
embedded specimens and adequate clinical history to
enable the following study. They were selected from par-
affin blocks archives of Oral and General Pathology
Departments, Faculty of Dentistry and Faculty of Medi-
cine, Mansoura University between 1998 to 2006. All
cases did not previously receive chemo-or radiotherapy
before the operation. Chondrosarcomas were graded
according to WHO classification [45]. The grading is
based primarily on nuclear size of tumor cells, nuclear
staining (hyperchromasia, or darker staining of nuclear
material) and cellularity. Mitotic figures and necrosis are
additional features useful in grading.
Two cases of normal cartilage were obtained from condy-
lar cartilage of a mandible recommended for hemimand-
ibulectomy due to evidence of squamous cell carcinoma
lesion.
I- Clinical study
The clinical data were collected retrospectively through
the computerized retrospective database from the tumor
registry, regarding age, sex, site and recurrence.
II- Histological study
Sections of 4 μm thickness were cut, deparaffinized, rehy-
drated and stained with (a) hematoxylin and eosin for re-
evaluation and confirmation of histopathological malig-
nancy grading diagnosis and (b) for the immunohisto-
chemical evaluation of MMP-13 expression.
III- Immunohistochemical study
Paraffin sections were employed for immunostaining for
collagenase-3 (MMP-13) (mouse monocolonal antibody)
clone (lab vision corporation VIII A2), by the standard
avidin-biotin peroxidase complex technique (ABC)
(Vectastain ABC kit; Vector Laboratories, Burlingame, CA,
USA), according to Hsu et al., [46]. Sections were rehy-
drated by passing through xylene and a series of graded
alcohols (90% to 70%), then to water. The rehydrated
slides were treated sequentially with 0.3% hydrogen per-
oxide (H2O2) in methanol for 30 minutes to block
endogenous peroxidase activity. The slides were placed in
10 mM citric acid buffer at pH 6.0 and underwent antigen
retrieval for 10 min at 750 w and 95°c in a microwave
oven followed by cooling at room temperature for 20
minutes. According to the manufacturer, the primary anti-
body MMP-13 (cat. ≠ 825- R7) is ready to use (7.0 ml),
applied on the sections, and stored overnight at 4°c. Then,
the slides were incubated with the second biotinylated
antibody and the avidin-biotin complex reagent (Vector
Laboratories, Burlingame, CA, USA). After 30 min at room
temperature, the reaction was developed with using
diaminobenzidine (DAB) as chromogen. The sections
were then counterstained with Mayer's hematoxylin
before mounting.
To guard against false negative and false positive results,
negative and positive control sections were used in each
batch.
Negative control sections were performed by substituting
non-immune serum for MMP-13. Positive control sec-
tions of human breast carcinoma were also included.
Staining assessment
Quantitation of immunoreactivity was performed using
an Olympus light microscope interfaced via a Sony cam-
era to an image analysis system (Qwin Pro, Leica, Wetzlar,
Germany). The percentages of collagenase-3. immunopo-
sitive cells were obtained from 20 random fields per case/
section using a 10× objective lens.
Semiquantitative estimation of collagenase-3 immunos-
taining intensities was made in immunopositive cells by
arbitrarily assigning as follows: negative (-) = 100% of
cells negative, mild (+) = (0% – < 25%) of cells positive,
moderate (++) = (25% – >50%) of cells positive and
intense (+++) = (75% – 100%) of the cells positive.
The staining intensity in MMP-13 positive cases was veri-
fied as follows:
￿ Strong: Densely stained reaction visible at low magnifi-
cation (objective 4×).
￿ Weak: faintly cytoplasmic reaction only visible using a
higher magnification.
Statistical analysis
Data were analyzed for significance of difference by chi-
square analysis of 2 × 2 contingency tables by the Kwikstat
computer program (Texa soft software) [47]. P-value is
considered significant when P ≤ 0.05.
Results
Clinical findings
In this study, eleven cases of chondrosarcoma of the jaws
were examined. The age of our patients ranged betweenDiagnostic Pathology 2008, 3:26 http://www.diagnosticpathology.org/content/3/1/26
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14–68 years with a mean of 39.7 years. Regarding the sex,
seven patients were males and four females. The most fre-
quent site of involvement was the mandible (eight cases)
followed in frequency by the maxilla, in the anterior
region (three cases). Three of whom had a recurrence.
Histopathological evaluation
Regarding the grading of chondrosarcoma, there were
four cases grade I (Fig. 1), five cases grade II (Fig. 2), and
two cases grade III (Fig. 3).
On microscopic analysis, lower grade chondrosarcomas
composed of lobules of chondrocytes in a chondriod
background, separated by fibrous septa (Fig. 1). By con-
trast, higher-grade lesions tend to harbor regions of
densely packed hyperchromatic malignant looking cells.
Myxoid changes or chondroid matrix liquefaction is a
common feature of chondrosarcomas particularly in
Grade II and Grade III lesions. Grade II (or intermediate
grade) is more cellular with a greater degree of nuclear aty-
pia, hyperchromasia and nuclear size (Fig. 2). Grade III
(or high grade) tumors have significant areas of marked
pleomorphism, large cells with more hyperchromatic
nuclei than grade II (Fig. 3). Occasional giant cells, abun-
dant necrosis and mitoses are frequently detected.
Mitotic counts were between 2 and 35 per 10 high power
field (mean = 8.5). Necrosis was present in 7 of cases: less
than 50% in 4 tumors and more than 50% in 3 tumors.
Immunohistochemical findings
Pattern of MMP-13 immunostaining
The positive immunohistochemical reactivity to MMP-13
appeared as brown cytoplasmic and nuclear staining reac-
tion was also identified in tumor cells (Fig. 4). There was
no positive staining for MMP-13 observed in normal car-
tilage.
Table 1 summarizes the intensity and percentage of
immunoreactive cells for the MMP-13 detected in the
present series. The overall immunoreactivity among the
Table 1: Immunohistochemical staining reaction for MMP-13 in normal cartilage and chondrocarcomas.
Samples No of cases Intensity of staining Percentage of positive cells (%)
Negative - Mild + Moderate ++ Intense +++
Normal cartilage 2 2 (100%) - - - -
GI chondrosarcoma 4 3 (75%) 1 (25%) - - 0 %–4.2 %
GII chondrosarcoma 5 - - 2 (40%) 3 (60%) 15.4%–30.8%
GIII chondrosarcoma 2 - - - 2 (100%) 37.6%–40.2%
(-) Negative : 100% of cells negative.
(+) Mild : 0% – < 25% of cells positive.
(++) Moderate : 25% – >50% of cells positive.
(+++) Intense : 75% – 100% of cells positive
Lobules of malignant chondrocytes in chondroid matrix (H &  E stain) Figure 1
Lobules of malignant chondrocytes in chondroid matrix (H & 
E stain).
Variation in the size of chondrocytes nuclei in the lacunae (H  &E stain) Figure 2
Variation in the size of chondrocytes nuclei in the lacunae (H 
&E stain).Diagnostic Pathology 2008, 3:26 http://www.diagnosticpathology.org/content/3/1/26
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currently employed chondrosarcomas was identified in
eight of eleven cases (72.8%). Only three cases failed to
reveal staining for MMP-13. Malignant chondrocytes
expression of MMP-13 was limited almost entirely to
high-grade lesions (grade II and grade III).
In grade I chondrosarcomas, one of four cases revealed
mild staining for MMP-13 (Fig. 5), while the other three
cases showed negative reaction.
In grade II chondrosarcomas, three of five cases showed
strong immunoreaction for MMP-13 (Fig. 6&7). While
the last two cases revealed moderate immunoreactivity.
In grade III chondrosarcomas, only two cases were exam-
ined and revealed strong MMP-13 immunoreactivity (Fig.
8).
The immunoreactive pattern of MMP-13 on chondrosar-
coma sections showed variable in intensity and percent-
age of positive cells in different fields in the same case
(Fig. 4). Moderate to strong MMP-13 immunoreactivity
was observed in the chondrocytes that were located near
blood vessels (Fig. 7 &9).
Relation between MMP-13 expression and clinico-
pathological parameters of chondrosarcomas (Table 2)
The correlation between MMP-13 expression and clinico-
pathological parameters of the jaws chondrosarcoma
cases is summarized Table 2. There was no significant dif-
ference between MMP-13 positive and negative groups
regarding to age and sex of the patients as well as tumor
site. In contrast, there was significant difference (P < 0.05)
between the two groups concerning the mitotic counts
and necrosis. Comparing the intensity of MMP-13 reac-
tion between low and high grade chondrosarcomas
revealed that the difference was significant (P < 0.05).
Regarding the recurrence, the highest expression of MMP-
13 was observed in all the examined specimens. However,
there was no significant correlation between MMP-13
expression in primary lesions and their local recurrence.
Discussion
Human collagenase-3 (MMP-13), a new member of the
MMP family, is expressed by breast tumors [30]. It is a
powerful collagenolytic and gelatinolytic enzyme that
preferentially cleaves type II collagen and it can therefore
be implied that this enzyme may play a considerable role
in connective tissue turnover [32]. MMP-13 plays an
important role in tumor progression in numerous human
malignancies [48], including colorectal cancer [49], breast
cancer [30], squamous cell carcinomas [36,37], and
melanoma [50].
Absence of MMP-13 expression in normal cartilage [41-
51] may be explained by the destruction of MMP-13 by
other peptidases related to digestion or possibly due to the
very low rate of its synthesis in this tissue [52]. Also, it
might be due to the prolonged duration of the slow proc-
ess of ossification that is preceded by cartilage matrix deg-
radation by this collagenase [41,42]. Normally, MMP-13
expression by chondrocytes appears to be limited to carti-
lage development. Chondrocytes produce MMP-13 to
remove type II collagen at the growth plate during bone
formation [41,42]. Whereas neoplastic chondrocytes were
the most immunoreactive cells in the tumor sections
examined. The involvement of chondrocytes in MMP-13
production in chondrosarcoma of jaws is related to their
roles in matrix turnover [32-52]. Chondrocytes maintain
Moderate positive nuclear and cytoplasmic MMP-13 immuno- reactivity in malignant chondrocytes (ABC DAB) Figure 4
Moderate positive nuclear and cytoplasmic MMP-13 immuno-
reactivity in malignant chondrocytes (ABC DAB).
Foci of malignant cartilage with anaplastic hyperchromatic  pleomorphic cells dispersed in myxoid stroma (H &E stain) Figure 3
Foci of malignant cartilage with anaplastic hyperchromatic 
pleomorphic cells dispersed in myxoid stroma (H &E stain).Diagnostic Pathology 2008, 3:26 http://www.diagnosticpathology.org/content/3/1/26
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the integrity of the cartilage in normal joints, but in the
pathological conditions, chondrocytes are influenced to
change their properties by the action of inflammatory
cytokines to begin secreting matrix-degrading enzymes
and to eventually cause tumor. Therefore, the relative role
of collagenase-3 in chondrosarcoma becomes important
[53].
In the current study, it is of interest that, despite the fact
that most of analyzed chondrosarcoma cases were posi-
tive for MMP-13 expression, there were clear variations in
the percentage of positive cells and the intensity of stain-
ing. The highest collagenase-3 (MMP-13) positive immu-
noreactivity was found among grade III chondrosarcoma
cases. While, the weakest reaction for MMP-13 was noted
in most cases of grade I chondrosarcoma. In accordance
with Uria et al [54], these variation in MMP-13 staining
intensity may be dependant on the biological behavior
and histopathological features (degree of cellularity and
pleomorphism) in this tumor.
Staining for MMP-13 is usually cytoplasmic but nuclear
staining was also seen in some cases. This finding was in
accordance with the results of other reports [49], its signif-
icance is undetermined, but its presence warrants docu-
mentation. This observation may be attributed to MMP-
13 Ab used here is over expressed in its early stages in the
nucleus or it may possibly due to alteration in the process-
ing or stability of MMP-13. Strong expression of cytoplas-
mic and nuclear MMP-13 was observed with high grade
tumors. Thus, nuclear MMP-13 staining may help to iden-
tify a category with worse prognosis in this tumor.
Strong immunoreactivity of MMP-13 in chondrocytes
located near blood vessels may be due to increased
response of malignant chondrocytes to the inductive
effect of the stimulatory factors produced by endothelial
cells such as different cytokines (IL-1β, TGF-β or TNF-α)
[18-56]. These factors were previously found to play
important roles in the induction of collagenase-3 in
fibroblasts, keratinocytes, or primary chondrocytes [39-
53].
Table 2: Correlation between MMP-13 expression and clinicopathological parameters of chondrosarcoma patients.
Parameter No. of patients MMP-13 immunostaining P-value
MMP-13 (-ve) (n = 3) % MMP-13 (+ve) (n = 8) %
Age
>60 6 2 (33.3%) 4(66.7%)
≤ 60 5 1 (20%) 4 (80%) NS
Sex
Male 7 2 (28.6%) 5(71.4%)
Female 4 1 (25%) 3(75%) NS
Site
Mandible 8 2 (25%) 6(75%)
Maxilla 3 1 (33.3%) 2(66.7%) NS
Mitosis
0 3 3 (100%) 0(0%)
1 4 0(0%) 4(100%)
2 2 0(0%) 2(100%) *S
32 0  ( 0 % ) 2  ( 1 0 0 % )
Necrosis
o 5 3 (60%) 2 (40%)
14 0  ( 0 % ) 4  ( 1 0 0 % ) * S
22 0  ( 0 % ) 2  ( 1 0 0 % )
Grades
G-I 4 3 (75%) 1 (25%)
G-II 5 0 (0%) 5 (100%) *S
G-III 2 0 (0%) 2 (100%)
Recurrence
+ 3 0(0%) 3 (100%)
- 8 3 (37.5%) 5 (62.5%) NS
P ≤ 0.05 means significant difference
*S = Signficant
NS = Not significant
Necrosis Non = "0", <50% = "1", ≥ 50% = "2".
Mitosis 0–9/10HPF = "1", 10–19/10HPF = "2", ≥ 20/10HPF = "3"Diagnostic Pathology 2008, 3:26 http://www.diagnosticpathology.org/content/3/1/26
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MMP-13 is over-expressed in breast carcinomas but not in
normal mammary gland nor in benign mammary lesions
[30-58]. Additional reports revealed similar results among
squamous cell carcinomas [18-56] and malignant
melanoma [50]. This observation suggests that up-regula-
tion of MMP-13 may be somewhat linked to the malig-
nant transformation and contribute to the progression of
these tumors [54]. MMP-13 could play a critical role in the
uncontrolled lytic processes occurring during malignant
progression. This possibility is consistent with biochemi-
cal properties of this enzyme which has been character-
ized as a potent proteinase with a wide substrate
specificity including a preferential degrading activity on
type II collagen [31-44] which is the most abundant type
in articular cartilage [60,61].
The increase in MMP-13 expression may be necessary for
the activation of other MMPs that have previously been
identified in chondrosarcoma such as MMP-2 and MMP-
9 [62] it is also activated by MMP-2, MMP-3, and MTI-
MMP [32]. Furthermore, it is logical that tumors have far
higher amounts of MMP-13 activity because this molecule
catalyses the breakdown of ECM necessary for invasion.
Similarly, normal chondrocytes have no requirement for
MMP-13 mediated ECM breakdown, or increased activa-
tion of other MMPs. These findings again strengthen the
link between MMP-13 expression and tumor progression.
The mechanisms involved in MMP-13 activation are com-
plex. Previous investigations reported that the production
of a growth factor called basic fibroblast growth factor
(bFGF) by the malignant chondrocytes that stimulates the
same cell to produce collagenase-3 (MMP-13) [23-64].
This factor might be responsible for the currently observed
increase expression of MMP-13 among the high-grade
cases of chondrosarcoma of jaws. The precise molecular
mechanisms responsible for collagenase-3 up-regulation
in chondrosarcoma cells in response to bFGF have not yet
been elucidated, although it is likely that members of the
FGF receptor family may be involved [62-65]. The availa-
bility of a phenotypically stable chondrosarcoma cell line
with ability to produce collagenase-3 after bFGF treatment
will be very helpful for further evaluation. The precise
mechanisms mediating the bFGF elicited induction of this
MMP gene in human chondrosarcoma [54]. These varia-
tions need further investigations to reveal possible impli-
cation to the clinical outcome.
Intense MMP-13 reaction in proliferating neoplastic chondro- cytes located near blood vessels (ABC DAB) Figure 7
Intense MMP-13 reaction in proliferating neoplastic chondro-
cytes located near blood vessels (ABC DAB).
Grade I chondrosarcoma shows mild positive cytoplasmic  and nuclear reaction to MMP-13 (ABC DAB) Figure 5
Grade I chondrosarcoma shows mild positive cytoplasmic 
and nuclear reaction to MMP-13 (ABC DAB).
Diffuse strong positive cytoplasmic & nuclear reaction to  MMP-13 in neoplastic chondrocytes (ABC DAB) Figure 6
Diffuse strong positive cytoplasmic & nuclear reaction to 
MMP-13 in neoplastic chondrocytes (ABC DAB).Diagnostic Pathology 2008, 3:26 http://www.diagnosticpathology.org/content/3/1/26
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Fong et al., [40] found that there was no significant asso-
ciation between MMP-13 expression and patient's age,
tumor site and local recurrence in chondrosarcomas. This
result was in accordance with our results.
A finding of particular interest in this study was the occur-
rence of positive MMP-13 in most of the mitotically active
cells. This finding may reflect the high expression of
MMP-13 in the cases with high score of mitosis. Accord-
ingly, it can be claimed that the presence of MMP-13
might be associated with proliferative activity and tumor
aggressiveness [50].
A significant association between MMP-13 expression and
patient's poor prognosis was observed in this study. This
finding was in agreement with previous reports on breast
carcinoma [35], oral squamous cell carcinoma [37] and
malignant melanoma [50]. On the contrary, others [14]
have found no correlation between MMP-13 over-expres-
sion and prognosis in chondrosarcoma. This confliction
can be attributed to variables in ethnic and environmental
factors influencing the tumor growth in different popula-
tions. However, the number of the cases that examined in
the present work is small to consider this a true conflic-
tion.
The ability to predict the biologic behavior of cartilagi-
nous neoplasms has been difficult and many studies have
sought to identify a marker for recurrence [66,67]. The
expression of MMP-13 was present in all the examined
specimens. However, it could not be correlated with dis-
ease recurrence. This result was in agreement with Scully
et al., [68] who found that the expression of MMP-13 has
no prognostic significance for recurrence in chondrosar-
coma. It has been reported that as a tumor dedifferentiates
and becomes more aggressive biologically, there is a phe-
notypic drift that results in increased amounts of type I
collagen being synthesized [69,70]. It is possible that spe-
cificity for cleavage of type I collagen may be more impor-
tant than that of type II collagen to permit cell egression
and this is what leads to the observed results.
The understanding of cancer pathogenesis is rapidly grow-
ing and evidence indicates that several molecular genetic
markers are involved in the initiation and/or progression
of the disease. The interactions of the molecular genetic
changes are complex; however, some may be important
targets for the development of specific inhibitors to serve
as potential chemotherapeutic agents. An extracellular
matrix and basement membrane turnover is regulated by
a delicate balance between the molecular factors that par-
ticipate in the production, activation, and inhibition of
MMPs and the production of natural tissue inhibitors of
matrix metalloproteinases (TIMPs) [71]. Because of their
central role in tumor invasion and metastasis, MMPs are
potential targets for therapeutic intervention. Several
investigations have demonstrated the effectiveness of
anti-MMP therapy [72]. A synthetic small molecule has
been shown to inhibit the endotoxin and cytokine-
induced synthesis of MMP [73]. The inhibition of MMPs
such as MMP-13 has produced encouraging results by
decreasing the number, size and speed of development of
metastatic nodules in animals [74]. In the present study,
the MMP-13 expression was detected in 72.8 % of the
samples. The fact that MMP-13 activation is likely to occur
in chondroasrcoma of the jaws may make it particularly
suitable for treatment with the emerging class of drugs to
block MMP-13 secretion and matrix invasion. Using
MMP-13 inhibition as one arm of a multitargeted
Moderate positive reaction for MMP-13 in malignant  chondrocytes located near blood vessels (ABC DAB) Figure 9
Moderate positive reaction for MMP-13 in malignant 
chondrocytes located near blood vessels (ABC DAB). Strong positive cytoplasmic and nuclear reaction for MMP-13  in highly anaplastic undifferentiated cells (ABC DAB) Figure 8
Strong positive cytoplasmic and nuclear reaction for MMP-13 
in highly anaplastic undifferentiated cells (ABC DAB).Diagnostic Pathology 2008, 3:26 http://www.diagnosticpathology.org/content/3/1/26
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approach will have benefits for the treatment of chon-
droasrcoma of the jaws, when a larger series of studies
confirms MMP-13 representation in these tumors. In
addition, considering the many factors involved such as
tissue inhibitors of metalloproteinases (TIMPs) or various
stimulating factors for MMPs, the relationship between
chondroasrcoma of the jaws and TIMPs and other sub-
types of MMPs in worthy of further studies.
Conclusion
1- On the basis of positive expression of MMP-13 in the
majority of chondrosarcoma of the jaws and absence of
detectable expression in normal cartilage, a possible role
for this metalloproteinase in the tumoral process is pro-
posed.
2- The present study provides evidence of the prognostic
significance of MMP-13 in chondrosarcoma of the jaws
where the association between this marker and mitotic
counts, necrosis and high grade tumors suggests the pos-
sible role of MMP-13 in determining the highly aggressive
tumors.
3- It may become a therapeutic target for jaws chondrosa-
rcoma's patients with MMP-13 positive tumor.
These results are preliminary because of the small sample
size and should be verified in a larger number of cases.
Further exploration of these findings and correlation with
clinical follow-up are needed to corroborate these associ-
ations. Similarly, it will be of interest to examine whether
the small percentage of benign lesions producing MMP-
13 could be indicative of an increased risk of malignant
transformation in these patients.
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